[go: up one dir, main page]

WO2018178770A3 - Methods and compositions for selection of functional oligonucleotides - Google Patents

Methods and compositions for selection of functional oligonucleotides Download PDF

Info

Publication number
WO2018178770A3
WO2018178770A3 PCT/IB2018/000418 IB2018000418W WO2018178770A3 WO 2018178770 A3 WO2018178770 A3 WO 2018178770A3 IB 2018000418 W IB2018000418 W IB 2018000418W WO 2018178770 A3 WO2018178770 A3 WO 2018178770A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
sequencing instrument
methods
aptamer
flow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/000418
Other languages
French (fr)
Other versions
WO2018178770A2 (en
WO2018178770A8 (en
Inventor
Ido Bachelet
Naom MAMET
Itai RUSINEK
Gil Harari
Anastasia SHAPIRO
Yaniv Amir
Erez Lavi
Almogit ABU-HOROWITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Augmanity Nano Ltd
Original Assignee
Augmanity Nano Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3058295A priority Critical patent/CA3058295A1/en
Priority to CN201880035961.2A priority patent/CN110892071A/en
Priority to EP18726527.7A priority patent/EP3601571A2/en
Priority to JP2019553852A priority patent/JP2020515271A/en
Priority to AU2018244947A priority patent/AU2018244947A1/en
Priority to IL269669A priority patent/IL269669B2/en
Priority to KR1020197031683A priority patent/KR20190134683A/en
Application filed by Augmanity Nano Ltd filed Critical Augmanity Nano Ltd
Publication of WO2018178770A2 publication Critical patent/WO2018178770A2/en
Priority to US16/165,267 priority patent/US10501743B2/en
Publication of WO2018178770A3 publication Critical patent/WO2018178770A3/en
Anticipated expiration legal-status Critical
Priority to US16/599,970 priority patent/US20200032266A1/en
Publication of WO2018178770A8 publication Critical patent/WO2018178770A8/en
Priority to US17/191,222 priority patent/US20210198674A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present disclosure describes compositions and methods for rapid selection of both binding and functional oligonucleotides (DNA, RNA, or any natural or synthetic analog of these). In certain embodiments, provided herein are flow cells (e.g., flow cells for an Illumina sequencing instrument or a Polonator sequencing instrument) comprising within its flow chamber a plurality of immobilized aptamer clusters (e.g., from an aptamer library described herein) and, optionally, one or more target cells (e.g., cancer cells, immune cells, etc.) and/or a detectable indicator of cellular function (e.g., a fluorescent indicator of apoptosis, cell proliferation, gene or protein expression, etc.). In certain embodiments, provided herein are methods of using such an aptamer cluster-containing flow cell to identify functional aptamers from an aptamer library (e.g., in a sequencing instrument, such as an Illumina sequencing instrument).
PCT/IB2018/000418 2017-03-30 2018-03-30 Methods and compositions for selection of functional oligonucleotides Ceased WO2018178770A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA3058295A CA3058295A1 (en) 2017-03-30 2018-03-30 Methods and compositions for selection of functional oligonucleotides
CN201880035961.2A CN110892071A (en) 2017-03-30 2018-03-30 Methods and compositions for functional oligonucleotide selection
EP18726527.7A EP3601571A2 (en) 2017-03-30 2018-03-30 Methods and compositions for selection of functional oligonucleotides
JP2019553852A JP2020515271A (en) 2017-03-30 2018-03-30 Methods and compositions for the selection of functional oligonucleotides
AU2018244947A AU2018244947A1 (en) 2017-03-30 2018-03-30 Methods and compositions for selection of functional oligonucleotides
IL269669A IL269669B2 (en) 2017-03-30 2018-03-30 Methods and preparations for the selection of functional oligonucleotides
KR1020197031683A KR20190134683A (en) 2017-03-30 2018-03-30 Methods and Compositions for Selection of Functional Oligonucleotides
US16/165,267 US10501743B2 (en) 2017-03-30 2018-10-19 Methods and compositions for selection of functional oligonucleotides
US16/599,970 US20200032266A1 (en) 2017-03-30 2019-10-11 Compositions for Selection of Aptamers
US17/191,222 US20210198674A1 (en) 2017-03-30 2021-03-03 Compositions for selection of aptamers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478993P 2017-03-30 2017-03-30
US62/478,993 2017-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/165,267 Continuation US10501743B2 (en) 2017-03-30 2018-10-19 Methods and compositions for selection of functional oligonucleotides

Publications (3)

Publication Number Publication Date
WO2018178770A2 WO2018178770A2 (en) 2018-10-04
WO2018178770A3 true WO2018178770A3 (en) 2019-02-07
WO2018178770A8 WO2018178770A8 (en) 2019-11-07

Family

ID=62223053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/000418 Ceased WO2018178770A2 (en) 2017-03-30 2018-03-30 Methods and compositions for selection of functional oligonucleotides

Country Status (9)

Country Link
US (3) US10501743B2 (en)
EP (1) EP3601571A2 (en)
JP (1) JP2020515271A (en)
KR (1) KR20190134683A (en)
CN (1) CN110892071A (en)
AU (1) AU2018244947A1 (en)
CA (1) CA3058295A1 (en)
IL (1) IL269669B2 (en)
WO (1) WO2018178770A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058295A1 (en) 2017-03-30 2018-10-04 Augmanity Nano Ltd Methods and compositions for selection of functional oligonucleotides
JP2020519615A (en) * 2017-05-08 2020-07-02 オーグマニティ ナノ リミテッド Treatment of rapidly evolving biological entities
KR20210096599A (en) * 2018-09-28 2021-08-05 어그매니티 나노 엘티디 Methods and compositions for selection of functional aptamers
WO2021052982A1 (en) * 2019-09-16 2021-03-25 Bracco Imaging Spa Ca-ix aptamers and diagnostic and therapeutic uses thereof
WO2024096642A1 (en) * 2022-11-02 2024-05-10 건국대학교 산학협력단 Dna aptamer for diagnosis or treatment of colorectal cancer
US20250215449A1 (en) * 2023-12-31 2025-07-03 Trenchant BioSystems, Inc. Method of using of a functionally closed cell processing system

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070329A1 (en) * 1999-05-14 2000-11-23 Brandeis University Nucleic acid-based detection
WO2003070984A1 (en) * 2002-02-15 2003-08-28 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
WO2005037053A2 (en) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
WO2009140326A2 (en) * 2008-05-16 2009-11-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Microfluidic isolation of tumor cells or other rare cells from whole blood or other liquids
WO2009151688A2 (en) * 2008-03-12 2009-12-17 Syracuse University Direct selection of structurally defined aptamers
WO2010023327A2 (en) * 2008-09-01 2010-03-04 Consiglio Nazionale Delle Ricerche Method for obtaining oligonucleotide aptamers and uses thereof
WO2011050000A2 (en) * 2009-10-20 2011-04-28 The Regents Of The University Of California Single molecule nucleic acid nanoparticles
WO2014088830A2 (en) * 2012-12-05 2014-06-12 The Regents Of The University Of California Screening of nucleic acid agents via particle display
WO2015077441A2 (en) * 2013-11-20 2015-05-28 University Of Florida Research Foundation, Incorporated Antibody and aptamer ensemble for cell isolation and enrichment
WO2015088455A1 (en) * 2013-12-13 2015-06-18 Nanobiz Nanobiyoteknolojik Sistemler Egitim Bilisim Danismanlik Ar-Ge San.Tic. Ltd. Sti. Aptamer-gated nanoparticles for lateral flow assays
WO2016025804A1 (en) * 2014-08-15 2016-02-18 Medimmune, Llc Detecting residual host cell proteins in recombinant protein preparations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938567B2 (en) * 2013-06-15 2018-04-10 Cornell University High-throughput RNA interaction assay
CA3058295A1 (en) 2017-03-30 2018-10-04 Augmanity Nano Ltd Methods and compositions for selection of functional oligonucleotides

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070329A1 (en) * 1999-05-14 2000-11-23 Brandeis University Nucleic acid-based detection
WO2003070984A1 (en) * 2002-02-15 2003-08-28 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
WO2005037053A2 (en) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
WO2009151688A2 (en) * 2008-03-12 2009-12-17 Syracuse University Direct selection of structurally defined aptamers
WO2009140326A2 (en) * 2008-05-16 2009-11-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Microfluidic isolation of tumor cells or other rare cells from whole blood or other liquids
WO2010023327A2 (en) * 2008-09-01 2010-03-04 Consiglio Nazionale Delle Ricerche Method for obtaining oligonucleotide aptamers and uses thereof
WO2011050000A2 (en) * 2009-10-20 2011-04-28 The Regents Of The University Of California Single molecule nucleic acid nanoparticles
WO2014088830A2 (en) * 2012-12-05 2014-06-12 The Regents Of The University Of California Screening of nucleic acid agents via particle display
WO2015077441A2 (en) * 2013-11-20 2015-05-28 University Of Florida Research Foundation, Incorporated Antibody and aptamer ensemble for cell isolation and enrichment
WO2015088455A1 (en) * 2013-12-13 2015-06-18 Nanobiz Nanobiyoteknolojik Sistemler Egitim Bilisim Danismanlik Ar-Ge San.Tic. Ltd. Sti. Aptamer-gated nanoparticles for lateral flow assays
WO2016025804A1 (en) * 2014-08-15 2016-02-18 Medimmune, Llc Detecting residual host cell proteins in recombinant protein preparations

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
COLLETT J R ET AL: "Functional RNA microarrays for high-throughput screening of antiprotein aptamers", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 338, no. 1, 16 December 2004 (2004-12-16), pages 113 - 123, XP004747522, ISSN: 0003-2697, DOI: 10.1016/J.AB.2004.11.027 *
JACOB M TOME ET AL: "Comprehensive analysis of RNA-protein interactions by high-throughput sequencing-RNA affinity profiling", NATURE METHODS, vol. 11, no. 6, 8 May 2014 (2014-05-08), New York, pages 683 - 688, XP055504077, ISSN: 1548-7091, DOI: 10.1038/nmeth.2970 *
JAN HOFFMANN ET AL: "Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, vol. 84A, no. 3, 16 July 2007 (2007-07-16), pages 614 - 621, XP055075888, ISSN: 1549-3296, DOI: 10.1002/jbm.a.31309 *
JASON D BUENROSTRO ET AL: "Quantitative analysis of RNA-protein interactions on a massively parallel array reveals biophysical and evolutionary landscapes", NATURE BIOTECHNOLOGY, vol. 32, no. 6, 13 April 2014 (2014-04-13), pages 562 - 568, XP055504072, ISSN: 1087-0156, DOI: 10.1038/nbt.2880 *
KIRBY R ET AL: "APTAMER-BASED SENSOR ARRAYS FOR THE DETECTION AND QUANTITATION OF PROTEINS", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 76, no. 14, 15 July 2004 (2004-07-15), pages 4066 - 4075, XP001209816, ISSN: 0003-2700, DOI: 10.1021/AC049858N *
LI YUAN ET AL: "Fabrication and characterization of RNA aptamer microarrays for the study of protein-aptamer interactions with SPR imaging", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD, vol. 34, no. 22, 27 November 2006 (2006-11-27), pages 6416 - 6424, XP002571829, ISSN: 0305-1048, [retrieved on 20061127], DOI: 10.1093/NAR/GKL738 *
MCCAULEY T G ET AL: "Aptamer-based biosensor arrays for detection and quantification of biological macromolecules", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 319, no. 2, 15 August 2003 (2003-08-15), pages 244 - 250, XP004437708, ISSN: 0003-2697, DOI: 10.1016/S0003-2697(03)00297-5 *
MINSEON CHO ET AL: "Array-based Discovery of Aptamer Pairs", ANALYTICAL CHEMISTRY, vol. 87, no. 1, 11 December 2014 (2014-12-11), US, pages 821 - 828, XP055449381, ISSN: 0003-2700, DOI: 10.1021/ac504076k *
O. S. KOLOVSKAYA ET AL: "DNA-aptamer/protein interaction as a cause of apoptosis and arrest of proliferation in Ehrlich ascites adenocarcinoma cells", BIOCHEMISTRY (MOSCOW) SUPPLEMENT SERIES A: MEMBRANE AND CELL BIOLOGY, vol. 8, no. 1, 1 January 2014 (2014-01-01), Moscow, pages 60 - 72, XP055504175, ISSN: 1990-7478, DOI: 10.1134/S1990747813050061 *
OKOCHI M ET AL: "High-throughput screening of cell death inducible short peptides from TNF-related apoptosis-inducing ligand sequence", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 580, no. 3, 6 February 2006 (2006-02-06), pages 885 - 889, XP028030434, ISSN: 0014-5793, [retrieved on 20060206], DOI: 10.1016/J.FEBSLET.2006.01.010 *
WEIAN SHENG ET AL: "Multivalent DNA Nanospheres for Enhanced Capture of Cancer Cells in Microfluidic Devices", ACS NANO, vol. 7, no. 8, 27 August 2013 (2013-08-27), US, pages 7067 - 7076, XP055234970, ISSN: 1936-0851, DOI: 10.1021/nn4023747 *

Also Published As

Publication number Publication date
CN110892071A (en) 2020-03-17
AU2018244947A1 (en) 2019-10-17
IL269669A (en) 2019-11-28
WO2018178770A2 (en) 2018-10-04
US20200032266A1 (en) 2020-01-30
JP2020515271A (en) 2020-05-28
EP3601571A2 (en) 2020-02-05
US20190040391A1 (en) 2019-02-07
WO2018178770A8 (en) 2019-11-07
US20210198674A1 (en) 2021-07-01
KR20190134683A (en) 2019-12-04
US10501743B2 (en) 2019-12-10
IL269669B1 (en) 2023-09-01
CA3058295A1 (en) 2018-10-04
IL269669B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
WO2018178770A8 (en) Methods and compositions for selection of functional oligonucleotides
Fuchs et al. Writing and reading H2B monoubiquitylation
Zhang et al. Role of the lncRNA–p53 regulatory network in cancer
EP4560022A3 (en) Large gene excision and insertion
Quante et al. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity
WO2020065404A3 (en) Methods and compositions for selection of functional aptamers
EP4368715A3 (en) Nucleic acid sequence analysis from single cells
WO2019090251A3 (en) Nucleic acid indexing techniques
MX2024007924A (en) Multiplexed genome editing.
Zaidi et al. Bivalent epigenetic control of oncofetal gene expression in cancer
Sun et al. MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells
NZ723570A (en) Compositions and methods for quantifying a nucleic acid sequence in a sample
EP4368992A3 (en) Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
Fang et al. Transcriptome sequencing reveals key pathways and genes associated with cisplatin resistance in lung adenocarcinoma A549 cells
Griseri et al. Regulation of the mRNA half-life in breast cancer
EP4600650A3 (en) Improved methods and compositions for synthetic biomarkers
Fang et al. LINC00941 promotes proliferation and metastasis of pancreatic adenocarcinoma by competitively binding miR-873-3p and thus upregulates ATXN2.
Ghosh et al. Selection of genes mediating certain cancers, using a neuro-fuzzy approach
Orafidiya et al. Crosstalk between long non coding RNAs, microRNAs and DNA damage repair in prostate cancer: new therapeutic opportunities?
O'Loghlen et al. CBX 7 and miR‐9 are part of an autoregulatory loop controlling p16 INK 4a
Song et al. MicroRNA-214 regulates immunity-related genes in bovine mammary epithelial cells by targeting NFATc3 and TRAF3
WO2016060537A3 (en) Probes and primers for the rapid and reliable quantification of the genes specific to prostate cancer, using suitable reference genes
Wang et al. Transcriptome Analysis of Long Noncoding RNAs in Toll‐Like Receptor 3‐Activated Mesenchymal Stem Cells
MX2015016114A (en) Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of hdac inhibitor treatment.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18726527

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3058295

Country of ref document: CA

Ref document number: 2019553852

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018244947

Country of ref document: AU

Date of ref document: 20180330

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197031683

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018726527

Country of ref document: EP

Effective date: 20191030